ValiGene and
Kimeragen,
Inc. announced on
February 22, 2000 that they will merge to create ValiGen, a EuroAmerican functional genomics company. The newly formed
ValiGen will combine the genomics platform under development at Valigene with chimeraplasty, the
unique gene correction technology being developed at Kimeragen. The new company will pursue
commercial opportunities for its technologies in three areas: ValiGen will apply its
genomics and chimeraplasty technologies to the identification and validation of novel targets for therapeutic intervention
against major diseases, both for commercial partners and for its own account. ValiGen will explore
aggressively the potential for chimeraplast-based gene repair therapeutics to treat human diseases
associated with particular mutations.
ValiGen will work with commercial partners in the global agriculture and food industries to use both
genomics and chimeroplasty in order to achieve seed and crop improvements without introducing
exogenous genetic material into the seed. |
